Physician profile
Mona P Chang
NPI 1639159825
$1,772.58
in general payments reported to CMS, 2019-2025
29 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $103 · 2021: $62.11 · 2022: $188 · 2023: $361 · 2024: $392 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $588.26 | 2023-2025 | Qulipta, Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $117.05 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Lilly USA, LLC | $101.65 | 2019-2025 | Emgality, Jardiance, Zepbound |
| Pfizer INC. | $96.95 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $90.06 | 2019-2025 | Airsupra |
| Amgen INC. | $75.38 | 2019-2024 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $72.03 | 2022 | |
| Sanofi Pasteur INC. | $61.85 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.19 | 2019-2020 | |
| Dexcom, INC. | $52.19 | 2025 | Dexcom G6 Transmitter |
| Alkermes, INC. | $45.49 | 2022-2025 | Vivitrol |
| Novartis Pharmaceuticals Corporation | $44.27 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $40.47 | 2019-2021 | |
| Harmony Biosciences LLC | $40.37 | 2025 | |
| Astellas Pharma US INC | $34.25 | 2019-2025 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $26.00 | 2025 | Wegovy |
| Cequr Corporation | $25.70 | 2024 | Cequr Simplicity |
| Mylan Specialty L.P. | $25.67 | 2019 | |
| Amarin Pharma, INC. | $24.95 | 2019-2020 | |
| Exact Sciences Corporation | $23.63 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $20.43 | 2019 | |
| Allergan, INC. | $15.52 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.76 | 2022 | |
| Merck Sharp & Dohme LLC | $14.52 | 2023 | Vaxneuvance, Proquad, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $14.40 | 2024 | Voquezna |
| Nevro Corp. | $13.84 | 2023 | Senza |
| Sanofi-Aventis U.S. LLC | $13.17 | 2019 | |
| Greenwich Biosciences, INC. | $12.28 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.